Regular price $0.00
A download link will be emailed after check out.
Braftovi (encorafenib) in combination with Erbitux (cetuximab) is a treatment option for patients with BRAF V600E-variant metastatic bowel cancer (mCRC) who have received prior systemic therapy.
